Nkarta Stock
Nkarta, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Paul J. Hastings
- Employees
- 106
- Market cap
- $129 M
- IPO
- 10/07/2020
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for…
Nkarta stock: price history
1D
-6.7%
1W
-20.0%
1M
-37.3%
6M
-48.1%
YTD
-2.7%
1Y
-27.7%
2Y
-58.5%
5Y
-90.2%
10Y
–
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~5% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Nkarta
Analyst assessment of Nkarta
PRICE TARGET LOW
US$9.00
CONSENSUS
US$9.00
MEDIAN
US$9.00
PRICE TARGET HIGH
US$9.00
1
STRONG BUY
9
BUY
2
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 14/08/2026
Nkarta stock metrics
P/E
-1.15
P/B
0.54
EV/EBITDA
-1.65
RETURN ON EQUITY
-16.3%
NET MARGIN
0.0%
DEBT/EQUITY
0.3
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
80.4%
FLOAT SHARES
57,570,438
AVG. DAILY VOLUME (30D)
705,840
Insider transactions (SEC)
HASTINGS PAUL J
Institutional holders
Comparable stocks
Frequently asked questions about Nkarta stock
What does Nkarta do?
Nkarta, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Paul J. Hastings, the company employs around 106 people.
The IPO was on 10/07/2020; the stock trades on NASDAQ under the ticker NKTX.
What do analysts say about Nkarta stock?
12 analysts rate the stock, the consensus is Buy (as of 14/08/2026).
The average price target is US$9.00, ranging from US$9.00 to US$9.00, with a median of US$9.00.
This is an external assessment, not a statement by Market Jury.
When does Nkarta report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly 5% stronger than usual.
Does Nkarta pay a dividend?
No, Nkarta currently does not pay a dividend.
Which stocks are comparable to Nkarta?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Nkarta stock analyzed?
Clicking "Analyze stock" lets five strategies assess Nkarta against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.